A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.
Non Small Cell Lung Cancer
DRUG: BMS-663513
To determine the MTD and assess safety and tolerability of single ascending doses of BMS-663513 when given in combination with radiotherapy alone or radiotherapy plus paclitaxel and carboplatin to subjects with Non Small Cell Lung Carcinoma, throughout the study
Assess the PKs of BMS-663513 and the effect of BMS-663513 on immune system markers, end of study|Describe anti-tumor activity, throughout the study|Obtain blood and plasma for exploratory research, several timepoints throughout the study|Obtain archival tissue for predictive marker research, at screening
The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.